Thus, targeting the specific inhibition of APE1/Ref-1 redox pathways while preserving the DNA repair pathway in intestinal inflammation is promising and a potential novel treatment for IBD and its associated enteric neuropathy (Figure 1). Here, APEX1 is linked to inflammatory bowel disease.